I don't really expect good news on the efficacy/peer review front.
First off, I find it hard to believe that thwy have been performing a peer review for the last 6 months. What are they doing - reviewing a 1000 page document?
We may get some news in other areas, such as concrete revenue numbers or a partnership of some sort, but I don't expect this soon either.
When it did the recent run to .0155, I thought it may have some continuation since:
1. The price has been so low for so long
2. They might have been (finally) finished diluting
It appears, however, that none of the above is not the case.
I unloaded half my position today based on the last fed days action. If it goes back under a penny I will consider buying some back. If it should soar on some good news that's fine too.
The only reason I am up on this ticker in the last year is due to constant flipping of at least a good part of my holdings, even though I could have sold much higher and avoided losing most of my profit.
To each his/her own.